If this breaks the $17 pricing this may be single digits Pre-launch... I understand DD assertion that this doesn’t have usual constraints of insurance reimbursement And formularies etc, but nevertheless I think it could be a slow uptake against the current champion.. Wall Street is not patient and shorting the launch mentality can still wreck havoc on stock while waiting to assemble a quality sales team to go against entrenched competitor...
Market Data 
Markets 
AI
